23 research outputs found
DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer
DNA hypomethylation-mediated activation of <i>Cancer/Testis Antigen 45</i> (<i>CT45</i>) genes is associated with disease progression and reduced survival in epithelial ovarian cancer
<div><p>Epithelial ovarian cancer (EOC) is a highly lethal malignancy due to a lack of early detection approaches coupled with poor outcomes for patients with clinically advanced disease. Cancer-testis (CT) or cancer-germline genes encode antigens known to generate spontaneous anti-tumor immunity in cancer patients. CT45 genes are a recently discovered 6-member family of X-linked CT genes with oncogenic function. Here, we determined CT45 expression in EOC and fully defined its epigenetic regulation by DNA methylation. <i>CT45</i> was silent and hypermethylated in normal control tissues, but a large subset of EOC samples showed increased <i>CT45</i> expression in conjunction with promoter DNA hypomethylation. In contrast, copy number status did not correlate with <i>CT45</i> expression in the TCGA database for EOC. <i>CT45</i> promoter methylation inversely correlated with both CT45 mRNA and protein expression, the latter determined using IHC staining of an EOC TMA. <i>CT45</i> expression was increased and <i>CT45</i> promoter methylation was decreased in late-stage and high-grade EOC, and both measures were associated with poor survival. <i>CT45</i> hypomethylation was directly associated with <i>LINE-1</i> hypomethylation, and <i>CT45</i> was frequently co-expressed with other CT antigen genes in EOC. Decitabine treatment induced CT45 mRNA and protein expression in EOC cells, and promoter transgene analyses indicated that DNA methylation directly represses <i>CT45</i> promoter activity. These data verify CT45 expression and promoter hypomethylation as possible prognostic biomarkers, and suggest CT45 as an immunological or therapeutic target in EOC. Treatment with decitabine or other epigenetic modulators could provide a means for more effective immunological targeting of CT45.</p></div
Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a Gynecologic Oncology Service
Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF
LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy
Synuclein-Îł (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease
Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment
Limit on B(s)0 oscillation using a jet charge method
A lower limit is set on the B_{s}^{0} meson oscillation parameter \Delta m_{s} using data collected from 1991 to 1994 by the ALEPH detector. Events with a high transverse momentum lepton and a reconstructed secondary vertex are used. The high transverse momentum leptons are produced mainly by b hadron decays, and the sign of the lepton indicates the particle/antiparticle final state in decays of neutral B mesons. The initial state is determined by a jet charge technique using both sides of the event. A maximum likelihood method is used to set a lower limit of \, \Delta m_{s}. The 95\% confidence level lower limit on \Delta m_s ranges between 5.2 and 6.5(\hbar/c^{2})~ps^{-1} when the fraction of b quarks from Z^0 decays that form B_{s}^{0} mesons is varied from 8\% to 16\%. Assuming that the B_{s}^{0} fraction is 12\%, the lower limit would be \Delta m_{s} > 6.1(\hbar/c^{2})~ps^{-1} at 95\% confidence level. For x_s = \Delta m_s \, \tau_{B_s}, this limit also gives x_s > 8.8 using the B_{s}^{0} lifetime of \tau_{B_s} = 1.55 \pm 0.11~ps and shifting the central value of \tau_{B_s} down by 1\sigma